These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37173953)

  • 1. Genome-Wide Screening Identifies Gene AKR1C1 Critical for Resistance to Pirarubicin in Bladder Cancer.
    Nie Z; Gao Y; Chen M; Peng Y; Guo N; Cao H; Huang D; Gao X; Zhang S
    Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillation.
    Tanimoto R; Saika T; Ebara S; Kobayashi Y; Nasu R; Yamada D; Takamoto H; Miyaji Y; Nasu Y; Tsushima T; Kumon H
    World J Urol; 2018 Jun; 36(6):889-895. PubMed ID: 29387931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of intensive instillation of low-dose pirarubicin vs. bacillus Calmette-Guérin in patients with high-risk non-muscle-invasive bladder cancer.
    Fujita N; Hatakeyama S; Momota M; Kido K; Narita T; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e17-684.e24. PubMed ID: 32278732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aldo-keto reductase 1C1 induced by interleukin-1β mediates the invasive potential and drug resistance of metastatic bladder cancer cells.
    Matsumoto R; Tsuda M; Yoshida K; Tanino M; Kimura T; Nishihara H; Abe T; Shinohara N; Nonomura K; Tanaka S
    Sci Rep; 2016 Oct; 6():34625. PubMed ID: 27698389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial.
    Zhou J; Li L; Li X; Yu Q; Cui S; Shu K; Liu J; Liu J; Ding D; Du T
    Int J Hyperthermia; 2019; 36(1):868-875. PubMed ID: 31452420
    [No Abstract]   [Full Text] [Related]  

  • 6. [Mechanism of intravesical instillation of pirarubicin for preventing recurrence of non-muscle invasive bladder cancer].
    Li Q; Xu T; Wang XF
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):904-7. PubMed ID: 20193328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NOS3 895G>T and CBR3 730G>A Are Associated with Recurrence Risk in Non-Muscle-Invasive Bladder Cancer with Intravesical Instillations of THP.
    Zhou Q; Ding W; Weng Y; Ding G; Xia G; Xu J; Xu K; Ding Q
    Chemotherapy; 2018; 63(4):191-197. PubMed ID: 30125887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The value of transurethral thulium laser en bloc resection combined with a single immediate postoperative intravesical instillation of pirarubicin in primary non-muscle-invasive bladder cancer.
    Xu S; Tan S; Wu T; Gu J; Xu L; Che X
    Lasers Med Sci; 2020 Oct; 35(8):1695-1701. PubMed ID: 31970565
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome-wide Meta-analysis Identifies Novel Genes Associated with Recurrence and Progression in Non-muscle-invasive Bladder Cancer.
    Galesloot TE; Grotenhuis AJ; Kolev D; Aben KK; Bryan RT; Catto JWF; Cheng KK; Conroy S; Dyrskjøt L; Fleshner NE; James ND; Lamy P; Lindskrog SV; Malats N; Mengual L; Verhaegh G; Zeegers MP; Kiemeney LALM; Vermeulen SH
    Eur Urol Oncol; 2022 Feb; 5(1):70-83. PubMed ID: 34353775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical application of drug sensitive gene detection in postoperative instillation for non-muscle invasive bladder cancer.
    Wang Z; Tang H; Xue Y; Xue L; Li H; Chong T
    BMC Nephrol; 2020 Oct; 21(1):426. PubMed ID: 33028224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DAB2IP regulates the chemoresistance to pirarubicin and tumor recurrence of non-muscle invasive bladder cancer through STAT3/Twist1/P-glycoprotein signaling.
    Wu K; Wang B; Chen Y; Zhou J; Huang J; Hui K; Zeng J; Zhu J; Zhang K; Li L; Guo P; Wang X; Hsieh JT; He D; Fan J
    Cell Signal; 2015 Dec; 27(12):2515-23. PubMed ID: 26410305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of c-MYC and polyamine metabolism in multiple drug resistance in bladder cancer investigated by metabonomics.
    Zhu Y; Piao C; Zhang Z; Jiang Y; Kong C
    Genomics; 2022 Jan; 114(1):125-137. PubMed ID: 34843906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dichloroacetate enhances the antitumor effect of pirarubicin via regulating the ROS-JNK signaling pathway in liver cancer cells.
    Yan XJ; Xie P; Dai XF; Chen LX; Sun LB; Li T; He WH; Xu ZZ; Huang G; He FT; Lian JQ
    Cancer Drug Resist; 2020; 3(4):947-958. PubMed ID: 35582217
    [No Abstract]   [Full Text] [Related]  

  • 14. Prognostic Value of BUB1 for Predicting Non-Muscle-Invasive Bladder Cancer Progression.
    Piao XM; You C; Byun YJ; Kang HW; Noh J; Lee J; Lee HY; Kim K; Kim WT; Yun SJ; Lee SC; Kang K; Kim YJ
    Int J Mol Sci; 2021 Nov; 22(23):. PubMed ID: 34884561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?
    Sylvester RJ; Oosterlinck W; Holmang S; Sydes MR; Birtle A; Gudjonsson S; De Nunzio C; Okamura K; Kaasinen E; Solsona E; Ali-El-Dein B; Tatar CA; Inman BA; N'Dow J; Oddens JR; Babjuk M
    Eur Urol; 2016 Feb; 69(2):231-44. PubMed ID: 26091833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
    Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
    Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo studies of pirarubicin-loaded SWNT for the treatment of bladder cancer.
    Chen G; He Y; Wu X; Zhang Y; Luo C; Jing P
    Braz J Med Biol Res; 2012 Aug; 45(8):771-6. PubMed ID: 22782557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Whole-genome CRISPR Screen Identifies a Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer.
    Goodspeed A; Jean A; Costello JC
    Eur Urol; 2019 Feb; 75(2):242-250. PubMed ID: 30414698
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer.
    Liu Z; Xing L; Zhu Y; Shi P; Deng G
    Heliyon; 2022 Jun; 8(6):e09643. PubMed ID: 35711974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.